Objective: To estimate the short-term efficacy of ustekinumab (UST) in patients with Crohn's disease (CD) and intestinal stricture.Design: This retrospective case-series included patients with CD and intestinal stricture. The characteristics and disease evaluation data of the included patients, including Crohn's Disease Activity Index (CDAI), Crohn's disease obstructive score (CDOS), fecal calprotectin (FCP), and hypersensitive C reactive protein (Hs-CRP), were collected at baseline. The

more »

... endpoint was a success at week 24, defined as UST continuation without other treatments (steroids, other anti-tumor necrosis factors, surgery, or endoscopic dilation); secondary endpoints were improvement of clinical evaluation and laboratory data at week 24 in the whole cohort.Results: A total 36 patients were screened, and 12 were included between July 2020 and July 2021. At week 24, 10/12 (83.3%) patients achieved success. Among these patients, 6/8 (75%) patients with symptomatic stricturing Crohn's disease (SSCD) achieved success. In SSCD patients with successful use of UST, CDOS and CDAI were significantly improved in all patients, and FCP improved in 5/6 (83.3%) patients at week 24. Only 2 (16.7%) patients accepted anal reconstruction or endoscopic balloon dilation (DBE) at follow-up. No severe adverse events occurred during the study.Conclusions: A successful response to UST was observed in more than three-quarters of CD patients with an intestinal stricture. In addition, UST showed good efficacy and safety in SSCD.